Skip to main content

Registration
IDWeek Learning Objective
Return to Sessions
and Exhibits
Chasing the Sun
Schedule
Speakers
Oral Abstracts
Posters
Featured Speakers
FAQ

IDWeek 2020 Main banner

Registration
IDWeek Learning Objective
Return to Sessions
and Exhibits
Chasing the Sun
Schedule
Speakers
Oral Abstracts
Posters
Featured Speakers
FAQ

Tweets by IDWeek 2020

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Chasing the Sun

Live

On Demand

Favorite
0 Like
Facebook
Tweet this
Print

Hal Martin, MD

Exec Director, Virology Clinical Research
Gilead Sciences

Disclosure: Gilead Sciences Inc. (Employee, Shareholder)

Poster(s):

1002 - A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis
1028 - Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
1046 - Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV

Designed by CadmiumCD |Technical Support |Give Feedback
© Copyright 2024 CadmiumCD. All Rights Reserved.